XIAOLING XIONG
Medical Practice at 194 St, Flushing, NY
License number
Florida 128417
Issued Date
May 18, 2016
Effective Date
May 18, 2016
Expiration Date
Jan 31, 2018
Category
Health Care
Type
Medical Doctor
Address
Address
2
73-71 194Th St, Flushing, NY 11366
800 Rose St STE MS117, Lexington, KY 40536
800 Rose St STE MS117, Lexington, KY 40536
Phone
(718) 598-1467
Professional information
Peptide Inhibitors Of Abl Kinases
US Patent:
2010018, Jul 22, 2010
Filed:
Nov 29, 2006
Appl. No.:
12/095728
Inventors:
Leszek Kotula - Marlboro NJ, US
Xiaoling Xiong - Fresh Meadows NY, US
Xiaoling Xiong - Fresh Meadows NY, US
International Classification:
A61K 38/16, C07K 7/08, C07K 14/00, C07K 17/00, A61K 38/10, A61P 35/00
US Classification:
514 12, 530327, 530324, 530350, 514 14
Abstract:
Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue (10) is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an Abl kinase. Further provided are methods of inhibiting an Abl kinase. Also provided are methods of treating a patient having a condition characterized by a mutant AbI kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant AbI kinase. Methods of labeling an AbI kinase are also provided. Additionally, methods of isolating an Abl kinase from a tissue are provided.
Peptide Inhibitors Of Abl Kinases
US Patent:
2012019, Jul 26, 2012
Filed:
Mar 7, 2012
Appl. No.:
13/414422
Inventors:
Leszek Kotula - Marlboro NJ, US
Xiaoling Xiong - Fresh Meadows NY, US
Xiaoling Xiong - Fresh Meadows NY, US
Assignee:
NEW YORK BLOOD CENTER, INC. - New York NY
International Classification:
G01N 33/53
US Classification:
435 78
Abstract:
Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue () is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an Abl kinase. Further provided are methods of inhibiting an Abl kinase. Also provided are methods of treating a patient having a condition characterized by a mutant Abl kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant Abl kinase. Methods of labeling an Abl kinase are also provided. Additionally, methods of isolating an Abl kinase from a tissue are provided.